About AIxCrypto Holdings, Inc.
https://qlgntx.comAIxCrypto Holdings, Inc., a clinical-stage therapeutics company, focuses on the development of treatments for adult and pediatric cancer. The company's lead program is QN-302, an investigational small molecule G-quadruplexes (G4)-selective transcription inhibitor, which is in Phase I clinical trial for the treatment of pancreatic cancer and other solid tumors.
CEO
Kevin A. Richardson
Compensation Summary
(Year )
ETFs Holding This Stock
Summary
Showing Top 1 of 1
Ratings Snapshot
Rating : B-
Price Target
About AIxCrypto Holdings, Inc.
https://qlgntx.comAIxCrypto Holdings, Inc., a clinical-stage therapeutics company, focuses on the development of treatments for adult and pediatric cancer. The company's lead program is QN-302, an investigational small molecule G-quadruplexes (G4)-selective transcription inhibitor, which is in Phase I clinical trial for the treatment of pancreatic cancer and other solid tumors.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $0 | $1.43M ▼ | $-2.04M ▼ | 0% | $-4.68 ▼ | $-1.58M ▼ |
| Q2-2025 | $0 | $1.68M ▼ | $-1.69M ▲ | 0% | $-1 ▲ | $-1.58M ▲ |
| Q1-2025 | $0 | $2.72M ▲ | $-2.65M ▼ | 0% | $-1.82 ▼ | $-2.57M ▼ |
| Q4-2024 | $0 | $1.33M ▲ | $-855.82K ▲ | 0% | $0 ▲ | $-749.82K ▲ |
| Q3-2024 | $0 | $1.27M | $-1.79M | 0% | $-4.7 | $-1.39M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $38.78M ▲ | $43.47M ▲ | $4.92M ▼ | $38.55M ▲ |
| Q2-2025 | $331.6K ▲ | $3.96M ▲ | $5.61M ▲ | $-1.65M ▼ |
| Q1-2025 | $30.21K ▼ | $2.85M ▼ | $2.81M ▲ | $33.13K ▼ |
| Q4-2024 | $1.17M ▲ | $4.69M ▲ | $2.01M ▼ | $2.68M ▲ |
| Q3-2024 | $388.15K | $2.31M | $4.45M | $-2.14M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $-2.04M ▼ | $-2.14M ▼ | $-291K ▲ | $40.88M ▲ | $38.45M ▲ | $-2.14M ▼ |
| Q2-2025 | $-1.69M ▲ | $-1.1M ▲ | $-1.21M ▼ | $2.61M ▲ | $301.39K ▲ | $-1.1M ▲ |
| Q1-2025 | $-2.65M ▼ | $-1.59M ▲ | $-305K ▲ | $750K ▼ | $-1.14M ▼ | $-1.59M ▲ |
| Q4-2024 | $-855.82K ▲ | $-2.27M ▼ | $-1.01M ▲ | $4.06M ▲ | $786.46K ▲ | $-2.27M ▼ |
| Q3-2024 | $-1.79M | $-1.8M | $-1.25M | $3.32M | $269.47K | $-1.8M |
CEO
Kevin A. Richardson
Compensation Summary
(Year )
ETFs Holding This Stock
Summary
Showing Top 1 of 1
Ratings Snapshot
Rating : B-